Insulin growth factor binding proteins as therapeutic targets in type 2 diabetes

Bibliography

• Clemmons DR. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol Metab Clin North Am 2012;41(2):425-43; vii-viii
   PubMed Web of Science ®Google Scholar
• Froesch ER, Hussain MA, Schmid C, Zapf J. Insulin-like growth factor I: physiology, metabolic effects and clinical uses. Diabetes Metab Rev 1996;12(3):195-215
   Google Scholar
• Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28(1):20-47
   PubMed Web of Science ®Google Scholar
• Yakar S, Liu J-L, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 1999;96(13):7324-9
   PubMed Web of Science ®Google Scholar
• Domené HM, Bengolea SV, Martínez AS, et al. Deficiency of the circulating insulin-like Growth factor system associated with inactivation of the acid-labile subunit gene. N Engl J Med 2004;350(6):570-7
   Google Scholar
• D'Ercole AJ, Calikoglu AS. Editorial review: the case of local versus endocrine IGF-I actions: the jury is still out. Growth Horm IGF Res 2001;11(5):261-5
   Google Scholar
• De Meyts P, Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 2002;1(10):769-83
   PubMed Web of Science ®Google Scholar
• Clemmons DR. Structural and functional analysis of insulin-like growth factors. Br Med Bull 1989;45(2):465-80
   Google Scholar
• LeRoith D, Werner H, Beitner-Johnson D, Roberts CT. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995;16(2):143-63
   PubMed Web of Science ®Google Scholar
• Harris LK, Westwood M. Biology and significance of signalling pathways activated by IGF-II. Growth Factors 2012;30(1):1-12
   PubMed Web of Science ®Google Scholar
• Belfiore A, Frasca F, Pandini G, et al. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009;30(6):586-623
   PubMed Web of Science ®Google Scholar
• Frasca F, Pandini G, Scalia P, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 1999;19(5):3278-88
   PubMed Web of Science ®Google Scholar
• Soos MA, Whittaker J, Lammers R, et al. Receptors for insulin and insulin-like growth factor-I can form hybrid dimers. Characterisation of hybrid receptors in transfected cells. Biochem J 1990;270(2):383-90
   Google Scholar
• Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4(7):505-18
   PubMed Web of Science ®Google Scholar
• Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16(1):3-34
   PubMed Web of Science ®Google Scholar
• Romanelli RJ, LeBeau AP, Fulmer CG, et al. Insulin-like growth factor type-I receptor internalization and recycling mediate the sustained phosphorylation of Akt. J Biol Chem 2007;282(31):22513-24
   PubMed Web of Science ®Google Scholar
• Sarfstein R, Werner H. Minireview: nuclear insulin and insulin-like growth factor-1 receptors: a novel paradigm in signal transduction. Endocrinology 2013;154(5):1672-9
   Google Scholar
• Sung M, Jeong MS, Jang SB. Biological characterization and structure based prediction of insulin-like growth factor binding protein-5. Biochem Biophys Res Commun 2010;403(2):230-6
   Google Scholar
• Frystyk J. Free insulin-like growth factors - measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res 2004;14(5):337-75
   PubMed Web of Science ®Google Scholar
• Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 1999;20(6):761-87
   PubMed Web of Science ®Google Scholar
• Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997;18(6):801-31
   PubMed Web of Science ®Google Scholar
• Binoux M, Hossenlopp P. Insulin-like growth factor (IGF) and IGF-binding proteins: comparison of human serum and lymph. J Clin Endocrinol Metab 1988;67(3):509-14
   Google Scholar
• Zapf J, Hauri C, Futo E, et al. Intravenously injected insulin-like growth factor (IGF) I/IGF binding protein-3 complex exerts insulin-like effects in hypophysectomized, but not in normal rats. J Clin Invest 1995;95:179-86
   PubMedGoogle Scholar
• Guler H-P, Zapf J, Schmid C, Froesch ER. Insulin-like growth factors I and II in healthy man. Acta Endocrinol (Copenh) 1989;121(6):753-8
   PubMedGoogle Scholar
• Zapf J, Hauri C, Waldvogel M, Froesch ER. Acute metabolic effects and half-lives of intravenously administered insulinlike growth factors I and II in normal and hypophysectomized rats. J Clin Invest 1986;77(6):1768-75
   Google Scholar
• Bayne ML, Applebaum J, Chicchi GG, et al. Structural analogs of human insulin-like growth factor I with reduced affinity for serum binding proteins and the type 2 insulin-like growth factor receptor. J Biol Chem 1988;263(13):6233-9
   Google Scholar
• Yamanaka Y, Wilson EM, Rosenfeld RG, Oh Y. Inhibition of insulin receptor activation by insulin-like growth factor binding proteins. J Biol Chem 1997;272(49):30729-34
   PubMed Web of Science ®Google Scholar
• Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002;23(6):824-54
   PubMed Web of Science ®Google Scholar
• Clemmons DR. Use of mutagenesis to probe IGF-binding protein structure/function relationships. Endocr Rev 2001;22(6):800-17
   PubMed Web of Science ®Google Scholar
• Møller AV, Jørgensen SP, Chen J-W, et al. Glycosaminoglycans increase levels of free and bioactive IGF-I in vitro. Eur J Endocrinol 2006;155(2):297-305
   Google Scholar
• Frystyk J. Quantification of the GH/IGF-axis components: lessons from human studies. Domest Anim Endocrinol 2012;43(2):186-97
   Google Scholar
• Conover CA. Key questions and answers about pregnancy-associated plasma protein-A. Trends Endocrinol Metab 2012;23(5):242-9
   PubMed Web of Science ®Google Scholar
• Li Y, Zhou C, Zhou X, et al. PAPP-A in cardiac and non-cardiac conditions. Clin Chim Acta 2013;417(0):67-72
   Google Scholar
• Ning Y, Schuller AGP, Conover CA, Pintar JE. Insulin-like growth factor (IGF) binding protein-4 is both a positive and negative regulator of IGF activity in vivo. Mol Endocrinol 2008;22(5):1213-25
   Google Scholar
• Ning Y, Schuller AGP, Bradshaw S, et al. Diminished growth and enhanced glucose metabolism in triple knockout mice containing mutations of insulin-like growth factor binding protein-3, -4, and -5. Mol Endocrinol 2006;20(9):2173-86
   Google Scholar
• Jones JI, Gockerman A, Busby WH, et al. Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci USA 1993;90(22):10553-7
   PubMed Web of Science ®Google Scholar
• Schedlich LJ, Le Page SL, Firth SM, et al. Nuclear import of insulin-like growth factor-binding protein-3 and -5 is mediated by the importin beta subunit. J Biol Chem 2000;275(31):23462-70
   PubMed Web of Science ®Google Scholar
• LeRoith D, Bondy C, Yakar S, et al. The somatomedin hypothesis: 2001. Endocr Rev 2001;22(1):53-74
   Google Scholar
• Boni-Schnetzler M, Schmid C, Meier PJ, Froesch ER. Insulin regulates insulin-like growth factor I mRNA in rat hepatocytes. Am J Physiol Endocrinol Metab 1991;260(6):E846-E51
   Google Scholar
• Leung K-C, Doyle N, Ballesteros M, et al. Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J Clin Endocrinol Metab 2000;85(12):4712-20
   Web of Science ®Google Scholar
• Fernández AM, Kim JK, Yakar S, et al. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 2001;15(15):1926-34
   Google Scholar
• LeRoith D, Yakar S. Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 2007;3(3):302-10
   Google Scholar
• Baxter RC, Twigg SM. Actions of IGF binding proteins and related proteins in adipose tissue. Trends Endocrinol Metab 2009;20(10):499-505
   PubMed Web of Science ®Google Scholar
• Siddals K, Westwood M, Gibson J, White A. IGF-binding protein-1 inhibits IGF effects on adipocyte function: implications for insulin-like actions at the adipocyte. J Endocrinol 2002;174(2):289-97
   Google Scholar
• Fukuoka H, Iida K, Nishizawa H, et al. IGF-I stimulates reactive oxygen species (ROS) production and inhibits insulin-dependent glucose uptake via ROS in 3T3-L1 adipocytes. Growth Horm IGF Res 2010;20(3):212-19
   Google Scholar
• Frick F, Oscarsson J, Vikman-Adolfsson K, et al. Different effects of IGF-I on insulin-stimulated glucose uptake in adipose tissue and skeletal muscle. Am J Physiol Endocrinol Metab 2000;278(4):E729-E37
   PubMed Web of Science ®Google Scholar
• Mur C, Valverde AM, Kahn CR, Benito M. Increased insulin sensitivity in IGF-I receptor–deficient brown adipocytes. Diabetes 2002;51(3):743-54
   Google Scholar
• Klöting N, Koch L, Wunderlich T, et al. Autocrine IGF-1 action in adipocytes controls systemic IGF-1 concentrations and growth. Diabetes 2008;57(8):2074-82
   PubMed Web of Science ®Google Scholar
• Engström BE, Burman P, Holdstock C, et al. Effects of gastric bypass on the GH/IGF-I axis in severe obesity – and a comparison with GH deficiency. Eur J Endocrinol 2006;154(1):53-9
   PubMed Web of Science ®Google Scholar
• Frystyk J, Skjærbæk C, Vestbo E, et al. Circulating levels of free insulin-like growth factors in obese subjects: the impact of Type 2 diabetes. Diabetes Metab Res Rev 1999;15(5):314-22
   Google Scholar
• Frystyk J, Vestbo E, Skjærbaek C, et al. Free insulin-like growth factors in human obesity. Metabolism 1995;44(Suppl 4):37-44
   Google Scholar
• Rasmussen MH, Hvidberg A, Juul A, et al. Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects. J Clin Endocrinol Metab 1995;80(4):1407-15
   PubMed Web of Science ®Google Scholar
• Conover CA, Lee PD, Kanaley JA, et al. Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans. J Clin Endocrinol Metab 1992;74(6):1355-60
   PubMed Web of Science ®Google Scholar
• Rasmussen MH. Obesity, growth hormone and weight loss. Mol Cell Endocrinol 2010;316(2):147-53
   Google Scholar
• Frystyk J, Brick DJ, Gerweck AV, et al. Bioactive insulin-Like growth factor-I in obesity. J Clin Endocrinol Metab 2009;94(8):3093-7
   Google Scholar
• Gleeson HK, Lissett CA, Shalet SM. Insulin-like growth factor-I response to a single bolus of growth hormone is increased in obesity. J Clin Endocrinol Metab 2005;90(2):1061-7
   Google Scholar
• Brugts MP, van Duijn CM, Hofland LJ, et al. IGF-I bioactivity in an elderly population: relation to insulin sensitivity, insulin levels, and the metabolic syndrome. Diabetes 2010;59(2):505-8
   Google Scholar
• Arafat AM, Weickert MO, Frystyk J, et al. The role of insulin-like growth factor (IGF) binding protein-2 in the insulin-mediated decrease in IGF-I bioactivity. J Clin Endocrinol Metab 2009;94(12):5093-101
   Google Scholar
• Sesti G, Sciacqua A, Cardellini M, et al. Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance. Diabetes Care 2005;28(1):120-5
   Google Scholar
• Colao A, Di Somma C, Cascella T, et al. Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. Eur J Endocrinol 2008;159(4):389-97
   Google Scholar
• Friedrich N, Thuesen B, Jørgensen T, et al. The association between IGF-I and insulin resistance: a general population study in Danish adults. Diabetes Care 2012;35(4):768-73
   PubMed Web of Science ®Google Scholar
• Sandhu MS, Heald AH, Gibson JM, et al. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 2002;359(9319):1740-5
   PubMed Web of Science ®Google Scholar
• Acerini CL, Dunger DB. Insulin-like growth factor-I for the treatment of type 1 diabetes. Diabetes Obes Metab 2000;2(6):335-43
   Google Scholar
• McDonald A, Williams RM, Regan FM, et al. IGF-I treatment of insulin resistance. Eur J Endocrinol 2007;157(Suppl 1):S51-S56
   Google Scholar
• Hussain MA, Schmitz O, Mengel A, et al. Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans. J Clin Invest 1993;92(5):2249-56
   PubMed Web of Science ®Google Scholar
• Cheetham TD, Jones J, Taylor AM, et al. The effects of recombinant insulin-like growth factor I administration on growth hormone levels and insulin requirements in adolescents with Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1993;36(7):678-81
   Google Scholar
• Laager R, Keller U. Effects of recombinant human insulin-like growth factor I and insulin on counterregulation during acute plasma glucose decrements in normal and Type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 1993;36(10):966-71
   Google Scholar
• Moses AC, Young SC, Morrow LA, et al. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 1996;45(1):91-100
   PubMed Web of Science ®Google Scholar
• Guler H-P, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 1987;317(3):137-40
   Google Scholar
• Yakar S, Liu J-L, Fernandez AM, et al. Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes 2001;50(5):1110-18
   PubMed Web of Science ®Google Scholar
• Leahy JL, Vandekerkhove KM. Insulin-like growth factor-I at physiological concentrations is a potent inhibitor of insulin secretion. Endocrinology 1990;126(3):1593-8
   Google Scholar
• Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21(3):215-44
   PubMed Web of Science ®Google Scholar
• Baxter RC, Daughaday WH. Impaired formation of the ternary insulin-like growth factor-binding protein complex in patients with hypoglycemia due to nonislet cell tumors. J Clin Endocrinol Metab 1991;73(4):696-702
   Google Scholar
• Frystyk J, Skjærbæk C, Zapf J, Ørskov H. Increased levels of circulating free insulin-like growth factors in patients with non-islet cell tumour hypoglycaemia. Diabetologia 1998;41(5):589-94
   Google Scholar
• Roelfsema V, Lane MH, Clark RG. Insulin-like growth factor binding protein (IGFBP) displacers: relevance to the treatment of renal disease. Pediatr Nephrol (Berlin, Germany) 2000;14(7):584-8
   Google Scholar
• Lowman HB, Chen YM, Skelton NJ, et al. Molecular mimics of insulin-like growth factor 1 (IGF-1) for inhibiting IGF-1:  IGF-binding protein interactions. Biochemistry 1998;37(25):8870-8
   Google Scholar
• Campbell PG, Durham SK, Hayes JD, et al. Insulin-like growth factor-binding protein-3 binds fibrinogen and fibrin. J Biol Chem 1999;274(42):30215-21
   Google Scholar
• Laursen LS, Overgaard MT, Weyer K, et al. Cell surface targeting of pregnancy-associated plasma protein a proteolytic activity. J Biol Chem 2002;277(49):47225-34
   Google Scholar
• Mikkelsen JH, Gyrup C, Kristensen P, et al. Inhibition of the proteolytic activity of pregnancy-associated plasma protein-A by targeting substrate exosite binding. J Biol Chem 2008;283(24):16772-80
   Google Scholar
• Glerup S, Kløverpris S, Laursen LS, et al. Cell surface detachment of pregnancy-associated plasma protein-A requires the formation of intermolecular proteinase-inhibitor disulfide bonds and glycosaminoglycan covalently bound to the inhibitor. J Biol Chem 2007;282(3):1769-78
   Google Scholar
• Pellitero S, Reverter JL, Pizarro E, et al. Pregnancy-associated plasma protein-a levels are related to glycemic control but not to lipid profile or hemostatic parameters in type 2 diabetes. Diabetes Care 2007;30(12):3083-5
   Google Scholar
• Aso Y, Okumura K-I, Wakabayashi S, et al. Elevated pregnancy-associated plasma protein-A in sera from type 2 diabetic patients with hypercholesterolemia: associations with carotid atherosclerosis and toe-brachial index. J Clin Endocrinol Metab 2004;89(11):5713-17
   PubMed Web of Science ®Google Scholar
• Goll D, Valery T, Li H, et al. The calpain system. Physiol Rev 2003;83(3):731-801
   PubMed Web of Science ®Google Scholar
• Ghosh M, Shanker S, Siwanowicz I, et al. Proteolysis of insulin-like growth factor binding proteins (IGFBPs) by calpain. Biol Chem 2005;386(1):85-93
   Google Scholar
• Paul DS, Harmon AW, Winston CP, Patel YM. Calpain facilitates GLUT4 vesicle translocation during insulin-stimulated glucose uptake in adipocytes. Biochem J 2003;376(3):625-32
   Google Scholar
• Turner MD, Cassell PG, Hitman GA. Calpain-10: from genome search to function. Diabetes Metab Res Rev 2005;21(6):505-14
   Google Scholar
• Lee PDK, Giudice LC, Conover CA, Powell DR. Insulin-like growth factor binding protein-1: recent findings and new directions. Proc Soc Exp Biol Med 1997;216(3):319-57
   Google Scholar
• Luo J, Murphy LJ. Differential expression of the insulin-like growth factor binding proteins in spontaneously diabetic rats. J Mol Endocrinol 1992;8(2):155-63
   Google Scholar
• Nyomba BLG, Berard L, Murphy LJ. Free Insulin-like growth factor I (IGF-I) in healthy subjects: relationship with IGF-binding proteins and insulin sensitivity. J Clin Endocrinol Metab 1997;82(7):2177-81
   Google Scholar
• Espelund U, Søndergaard K, Bjerring P, et al. Interstitial fluid contains higher in vitro IGF bioactivity than serum: a study utilizing the suction blister technique. Growth Horm IGF Res 2012;22(6):234-9
   Google Scholar
• Hilding A, Brismar K, Thorén M, Hall K. Glucagon stimulates insulin-like growth factor binding protein-1 secretion in healthy subjects, patients with pituitary insufficiency, and patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993;77(5):1142-7
   Google Scholar
• Brismar K, Grill V, Efendic S, Hall K. The insulin-like growth factor binding protein-1 in low and high insulin responders before and during dexamethasone treatment. Metabolism 1991;40(7):728-32
   PubMedGoogle Scholar
• Brismar K, Fernqvist-Forbes E, Wahren J, Hall K. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab 1994;79(3):872-8
   PubMed Web of Science ®Google Scholar
• Hilding A, Brismar K, Degerblad M, et al. Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects. J Clin Endocrinol Metab 1995;80(9):2646-52
   Google Scholar
• Hong Y, Pedersen NL, Brismar K, et al. Quantitative genetic analyses of insulin-like growth factor I (IGF-I), IGF-binding protein-1, and insulin levels in middle-aged and elderly twins. J Clin Endocrinol Metab 1996;81(5):1791-7
   Google Scholar
• Wheatcroft SB, Kearney MT. IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis. Trends Endocrinol Metab 2009;20(4):153-62
   Google Scholar
• Weaver JU, Holly JM, Kopelman PG, et al. Decreased sex hormone binding globulin (SHBG) and insulin-like growth factor binding protein (IGFBP-1) in extreme obesity. Clin Endocrinol (Oxf) 1990;33(3):415-22
   Google Scholar
• Heald AH, Cruickshank JK, Riste LK, et al. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 2001;44(3):333-9
   PubMed Web of Science ®Google Scholar
• Mohamed-Ali V, Pinkney JH, Panahloo A, et al. Insulin-like growth factor binding protein-1 in NIDDM: relationship with the insulin resistance syndrome. Clin Endocrinol (Oxf) 1999;50(2):221-8
   Google Scholar
• Clauson PG, Brismar K, Hall K, et al. Insulin-like growth factor-I and insulin-like growth factor binding protein-1 in a representative population of type 2 diabetic patients in Sweden. Scand J Clin Lab Invest 1998;58(4):353-60
   PubMed Web of Science ®Google Scholar
• Rajkumar K, Modric T, Murphy L. Impaired adipogenesis in insulin-like growth factor binding protein-1 transgenic mice. J Endocrinol 1999;162(3):457-65
   Google Scholar
• Rajkumar K, Dheen ST, Murphy LJ. Hyperglycemia and impaired glucose tolerance in IGF binding protein-1 transgenic mice. Am J Physiol Endocrinol Metab 1996;270(4):E565-E71
   Google Scholar
• Leu JI, Crissey MAS, Craig LE, Taub R. Impaired hepatocyte DNA synthetic response posthepatectomy in insulin-like growth factor binding protein 1-deficient mice with defects in C/EBPβ and mitogen-activated protein kinase/extracellular signal-regulated kinase regulation. Mol Cell Biol 2003;23(4):1251-9
   PubMedGoogle Scholar
• Cingel-Ristić V, van Neck JW, Frystyk J, et al. Administration of human insulin-like growth factor-binding protein-1 increases circulating levels of growth hormone in mice. Endocrinology 2004;145(9):4401-7
   Google Scholar
• Lang CH, Vary TC, Frost RA. Acute in vivo elevation of insulin-like growth factor (IGF) binding protein-1 decreases plasma free IGF-I and muscle protein synthesis. Endocrinology 2003;144(9):3922-33
   Google Scholar
• Lewitt MS, Denyerf GS, Cooney J G, Baxter RC. Insulin-like growth factor-binding protein-1 modulates blood glucose levels. Endocrinology 1991;129(4):2254-6
   PubMed Web of Science ®Google Scholar
• Wheatcroft SB, Kearney MT, Shah AM, et al. Vascular endothelial function and blood pressure homeostasis in mice over expressing IGF binding protein-1. Diabetes 2003;52(8):2075-82
   Google Scholar
• Heald AH, Siddals KW, Fraser W, et al. Low Circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type 2 diabetes. Diabetes 2002;51(8):2629-36
   Google Scholar
• Motaghedi R, Gujral S, Sinha S, et al. Insulin-like growth factor binding protein-1 to screen for insulin resistance in children. Diabetes Technol Ther 2007;9(1):43-51
   Google Scholar
• Wang J, Razuvaev A, Folkersen L, et al. The expression of IGFs and IGF binding proteins in human carotid atherosclerosis, and the possible role of IGF binding protein-1 in the regulation of smooth muscle cell proliferation. Atherosclerosis 2012;220(1):102-9
   Google Scholar
• Ruotolo G, Båvenholm P, Brismar K, et al. Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment. J Am Coll Cardiol 2000;35(3):647-54
   Google Scholar
• Mellbin LG, Rydén L, Brismar K, et al. Copeptin, IGFBP-1, and cardiovascular prognosis in patients with type 2 diabetes and acute myocardial infarction: a report from the DIGAMI 2 trial. Diabetes Care 2010;33(7):1604-6
   Google Scholar
• Wallander M, Norhammar A, Malmberg K, et al. IGF binding protein 1 predicts cardiovascular morbidity and mortality in patients with acute myocardial infarction and type 2 diabetes. Diabetes Care 2007;30(9):2343-8
   Google Scholar
• Petersson U, Ostgren CJ, Brudin L, et al. Low levels of insulin-like growth-factor-binding protein-1 (IGFBP-1) are prospectively associated with the incidence of type 2 diabetes and impaired glucose tolerance (IGT): the Soderakra Cardiovascular Risk Factor Study. Diabetes Metab 2009;35(3):198-205
   PubMed Web of Science ®Google Scholar
• Lewitt MS, Hilding A, Brismar K, et al. IGF-binding protein 1 and abdominal obesity in the development of type 2 diabetes in women. Eur J Endocrinol 2010;163(2):233-42
   Google Scholar
• Lewitt MS, Hilding A, Östenson CG, et al. Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men. Diabetologia 2008;51(7):1135-45
   Google Scholar
• Wolk K, Larsson SC, Vessby B, et al. Metabolic, anthropometric, and nutritional factors as predictors of circulating insulin-like growth factor binding protein-1 levels in middle-aged and elderly men. J Clin Endocrinol Metab 2004;89(4):1879-84
   Google Scholar
• Clemmons D, Snyder D, Busby W. Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects. J Clin Endocrinol Metab 1991;73(4):727-33
   Google Scholar
• Hedbacker K, Birsoy KV, Wysocki RW, et al. Antidiabetic effects of IGFBP2, a Leptin-regulated gene. Cell Metab 2010;11(1):11-22
   PubMed Web of Science ®Google Scholar
• Hertel JK, Johansson S, Ræder H, et al. Genetic analysis of recently identified type 2 diabetes loci in 1,638 unselected patients with type 2 diabetes and 1,858 control participants from a Norwegian population-based cohort (the HUNT study). Diabetologia 2008;51(6):971-7
   Google Scholar
• Grarup N, Rose CS, Andersson EA, et al. Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10,705 danish subjects: validation and Extension of Genome-Wide Association Studies. Diabetes 2007;56(12):3105-11
   Google Scholar
• Boney CM, Moats-Staats BM, Stiles AD, D'Ercole AJ. Expression of insulin-like growth factor-I (IGF-I) and IGF-binding proteins during adipogenesis. Endocrinology 1994;135(5):1863-8
   PubMed Web of Science ®Google Scholar
• Wheatcroft SB, Kearney MT, Shah AM, et al. IGF-binding protein-2 protects against the development of obesity and insulin resistance. Diabetes 2007;56(2):285-94
   PubMed Web of Science ®Google Scholar
• Heald AH, Kaushal K, Siddals KW, et al. Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome. Exp Clin Endocrinol Diabetes 2006;114(07):371-6
   Google Scholar
• Pintar JE, Schuller A, Cerro JA, et al. Genetic ablation of IGFBP-2 suggests functional redundancy in the IGFBP family. Prog Growth Factor Res 1995;6(2–4):437-45
   Google Scholar
• Wood TL, Rogler LE, Czick ME, et al. Selective alterations in organ sizes in mice with a targeted disruption of the insulin-like growth factor binding protein-2 gene. Mol Endocrinol 2000;14(9):1472-82
   PubMedGoogle Scholar
• Bang P, Brismar K, Rosenfeld RG. Increased proteolysis of insulin-like growth factor-binding protein-3 (IGFBP-3) in noninsulin-dependent diabetes mellitus serum, with elevation of a 29-kilodalton (kDa) glycosylated IGFBP-3 fragment contained in the approximately 130- to 150-kDa ternary complex. J Clin Endocrinol Metab 1994;78(5):1119-27
   Google Scholar
• Rajpathak SN, He M, Sun Q, et al. Insulin-like growth factor axis and risk of type 2 diabetes in women. Diabetes 2012;61(9):2248-54
   PubMedGoogle Scholar
• Muzumdar RH, Ma X, Fishman S, et al. Central and opposing effects of IGF-I and IGF-binding protein-3 on systemic insulin action. Diabetes 2006;55(10):2788-96
   Google Scholar
• Kim HS, Ali O, Shim M, et al. Insulin-like growth factor binding protein-3 induces insulin resistance in adipocytes in vitro and in rats in vivo. Pediatr Res 2007;61(2):159-64
   Google Scholar
• Chan SSY, Twigg SM, Firth SM, Baxter RC. Insulin-like growth factor binding protein-3 leads to insulin resistance in adipocytes. J Clin Endocrinol Metab 2005;90(12):6588-95
   Google Scholar
• Silha JV, Gui Y, Murphy LJ. Impaired glucose homeostasis in insulin-like growth factor-binding protein-3-transgenic mice. Am J Physiol Endocrinol Metab 2002;283(5):E937-E45
   Google Scholar
• Grinspoon S, Clemmons D, Swearingen B, Klibanski A. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly. J Clin Endocrinol Metab 1995;80(3):927-32
   Google Scholar
• Juul A, Scheike T, Davidsen M, et al. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease. Circulation 2002;106(8):939-44
   PubMed Web of Science ®Google Scholar
• Giudice LC. IGF binding protein-3 protease regulation: how sweet it is!. J Clin Endocrinol Metab 1995;80(8):2279-81
   Google Scholar
• Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3. Drugs R&D 2005;6(2):120-7
   Google Scholar
• Rao MN, Mulligan K, Tai V, et al. Effects of insulin-like growth factor (IGF)-I/IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance. J Clin Endocrinol Metab 2010;95(9):4361-6
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes - 2013. Diabetes Care 2013;36(Suppl 1):S11-66
   PubMed Web of Science ®Google Scholar